Ascendis Pharma A/S

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 2006-01-01

Employees: 14

Market Cap: $7.9B

Website: http://www.ascendispharma.com

Introduction: Ascendant Resources Inc is a mining company. The company is engaged in evaluating resource opportunities. The Company’s sole investment and exploration activities are in the Lagoa Salgada Project in Portugal. It is focused on its own producing El Mochito zinc, silver and lead mine. The El Mochito mine is located in northwestern Honduras. The underground operation takes advantage of selective and bulk underground mining methods to mine multiple flat-lying manto deposits and high-grade vertical chimneys, producing zinc and lead concentrates with silver credits.

Clinical Trials

A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide in Adolescents (12 - 18 Years of Age) With Achondroplasia.

Phase 2

Recruiting

Conditions: Achondroplasia

Interventions: Drug: Navepegritide
Drug: Placebo for navepegritide

First Posted Date: 2024-12-13

Last Posted Date: 2025-05-21

Lead Sponsor: Ascendis Pharma A/S

Target Recruit Count: 24

Registration Number: NCT06732895

Locations: 🇫🇷
Ascendis Investigational Site, Paris, France

A Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of Multiple Subcutaneous Doses of TransCon CNP Administered Once Weekly in Children With Achondroplasia

Phase 2

Active, not recruiting

Conditions: Achondroplasia

Interventions: Drug: TransCon CNP
Drug: Placebo for TransCon CNP

First Posted Date: 2022-02-18

Last Posted Date: 2023-11-02

Lead Sponsor: Ascendis Pharma A/S

Target Recruit Count: 24

Registration Number: NCT05246033

Locations: 🇨🇳
Ascendis Pharma Investigational Site, Wuhan, China

A Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of TransCon CNP Administered Once Weekly in Prepubertal Children With Achondroplasia

Phase 2

Completed

Conditions: Achondroplasia

Interventions: Drug: TransCon CNP
Drug: Placebo for TransCon CNP

First Posted Date: 2019-09-11

Last Posted Date: 2024-10-29

Lead Sponsor: Ascendis Pharma A/S

Target Recruit Count: 57

Registration Number: NCT04085523

Locations: 🇵🇹
Ascendis Pharma Investigational Site, Coimbra, Portugal

A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With Hypoparathyroidism

Phase 2

Completed

Conditions: Hypoparathyroidism
Endocrine System Diseases
Parathyroid Diseases

Interventions: Combination Product: TransCon PTH
Combination Product: Placebo for TransCon PTH

First Posted Date: 2019-07-05

Last Posted Date: 2025-05-08

Lead Sponsor: Ascendis Pharma A/S

Target Recruit Count: 59

Registration Number: NCT04009291

Locations: 🇳🇴
Ascendis Pharma Investigational Site, Oslo, Norway

A Multi-center, Longitudinal, Observational Study of Children With Achondroplasia

Completed

Conditions: Achondroplasia

First Posted Date: 2019-03-14

Last Posted Date: 2024-03-19

Lead Sponsor: Ascendis Pharma A/S

Target Recruit Count: 260

Registration Number: NCT03875534

Locations: 🇬🇧
Ascendis Pharma Investigational Site, London, United Kingdom

A Safety, Tolerability and Pharmacokinetics Study of TransCon Treprostinil in Healthy Adult Male Volunteers

Phase 1

Terminated

Conditions: Healthy Volunteers

Interventions: Drug: TransCon Treprostinil

First Posted Date: 2019-01-14

Last Posted Date: 2019-01-14

Lead Sponsor: Ascendis Pharma A/S

Target Recruit Count: 20

Registration Number: NCT03803163

A Long-Term Trial Investigating Safety and Efficacy of TransCon hGH in Children With Growth Hormone Deficiency Who Have Completed a Prior TransCon hGH Clinical Trial

Phase 3

Completed

Conditions: Growth Hormone Deficiency, Pediatric
Endocrine System Diseases
Hormone Deficiency
Pituitary Diseases

Interventions: Drug: TransCon hGH

First Posted Date: 2017-11-17

Last Posted Date: 2024-05-08

Lead Sponsor: Ascendis Pharma A/S

Target Recruit Count: 298

Registration Number: NCT03344458

Locations: 🇺🇦
Ascendis Pharma Investigational Site, Odesa, Ukraine

Safety, PK/PD (Pharmacokinetics/Pharmacodynamics) and Efficacy of ACP-001 Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)

Phase 2

Completed

Conditions: Growth Hormone Deficiency (GHD)

Interventions: Drug: ACP-001
Drug: Human Growth Hormone

First Posted Date: 2013-09-23

Last Posted Date: 2017-01-19

Lead Sponsor: Ascendis Pharma A/S

Target Recruit Count: 53

Registration Number: NCT01947907

Locations: 🇺🇦
Kharkiv National Medical University, Kharkiv, Ukraine
🇺🇦
Institute of Endocrinology and Metabolism, Kiev, Ukraine
🇺🇦
Donetsk Regional Children Clinical Hospital, Donetsk, Ukraine

and more 33 locations

A Safety, Pharmacokinetic and Pharmacodynamic Study of ACP-001 (TransCon hGH) in Adults With Growth Hormone Deficiency

Phase 2

Completed

Conditions: Adult Growth Hormone Deficiency

Interventions: Drug: ACP-001 (TransCon hGH)
Drug: Omnitrope

First Posted Date: 2010-11-24

Last Posted Date: 2017-03-09

Lead Sponsor: Ascendis Pharma A/S

Target Recruit Count: 37

Registration Number: NCT01247675

Locations: 🇩🇪
Charité University Hospital Berlin, Berlin, Germany
🇩🇰
Aarhus University Hospital, Aarhus, Denmark
🇸🇪
Karolinska University Hospital, Stockholm, Sweden

and more 1 locations

Pharmacokinetics and Pharmacodynamics of ACP-001 (TransCon PEG hGH)

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: ACP-001 (TransCon PEG hGH)
Drug: Placebo
Drug: Human Growth Hormone

First Posted Date: 2009-11-10

Last Posted Date: 2010-06-08

Lead Sponsor: Ascendis Pharma A/S

Target Recruit Count: 44

Registration Number: NCT01010425

Home Terms & Conditions Privacy Policy